Pentamidine and death domain receptor ligand united application

A combined application, pentamidine technology, applied in the field of medicine, can solve the problem of enhancing the sensitivity of leukemia cells to induce apoptosis, and achieve the effect of treating leukemia and enhancing sensitivity
CN101138558AInactive Publication Date: 2008-03-12SHANTOU UNIV MEDICAL COLLEGE
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
SHANTOU UNIV MEDICAL COLLEGE
Publication Date
2008-03-12
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention belongs to the pharmaceutical field. The present invention particularly relates to the medicine of pentamidine combined with the legend of the death structure receptor in treating the tumor and the leukemia. The ligand of the death structure receptor in the present invention comprises TRAIL, TNF-alpha or the analogues, which is the combination of the pentamidine with the metabolite or the analogues. The benefit of the present invention is that the pentamidine sensibility of the leukemia cell of the ligand of the death structure receptor. In the clinical field, when the pentamidine of the therapeutic drug concentration is applied in the leukemia cell, which is tolerant to the ligand of the death structure receptor, the apoptosis can be induced; therefore the purpose for the leukemia treatment is realized.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of medicines, in particular to medicines for treating tumors and leukemias with pentamidine combined with death domain receptor ligands. technical background:

[0002] Leukemia is a malignant tumor of the hematopoietic system. Since the first leukemia patient achieved clinical remission with chemotherapy in 1947, the treatment of leukemia has developed from simple chemotherapy to the comprehensive application of hematopoietic stem cell transplantation, biological therapy (including cytokines, immunotherapy, etc.), but so far The effect of leukemia treatment is still unsatisfactory. Therefore, how to establish new low-toxicity and high-efficiency leukemia treatment-related strategies is still the focus of researchers. In the normal human hematopoietic system, cell growth maintains a steady state, determined by the balance between cell proliferation and renewal and cell death. When this homeostasis imbalance is disru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More